Celcuity Announces Updated Clinical Results for Gedatolisib in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc. announced updated clinical results for gedatolisib in a Phase 1b/2 study for metastatic castration-resistant prostate cancer, revealing a median radiographic progression-free survival of 15.7 months for patients previously treated with abiraterone and 9.1 months for those treated with enzalutamide. The study included 45 patients across three dose-finding arms. The Phase 2 portion of the study is expected to begin in the first half of 2027, highlighting the potential of Celcuity's targeted therapy candidate.